LIPO Lipella Pharmaceuticals Inc. logo

LIPO Lipella Pharmaceuticals Inc.

Healthcare
$0.10-28.57%ClosedMarket Cap: $462,084

As of 2026-05-25

Valuation

View Details

P/E (TTM)

PEG

P/B

0.31

P/S

2.66

EV/EBITDA

0.21

DCF Value

$-7.42

FCF Yield

-511078.4%

Div Yield

0.0%

Margins & Returns

Gross Margin

-1954.7%

Operating Margin

-3115.2%

Net Margin

-3069.0%

ROE

-208.4%

ROA

-226.8%

ROIC

-308.8%

Financials

View All
PeriodRevenueNet IncomeEPS
Q3 null$0.00$-1.3M$
Q2 null$0.00$-1.3M$
Q1 null$0.00$-1.3M$
Q4 null$173.7K$-1.4M$

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$2.00

Target (Median)

$2.00

Target Range

$2.00 - $2.00

1 Strong Buy0 Buy0 Hold0 Sell0 Strong Sell

Trading Activity

Insider Trades

View All
Kaufman Jonathan Hdirector, 10 percent owner, officer: See remarks below.
SellMon Apr 07
Kaufman Jonathan Hdirector, 10 percent owner, officer: See remarks below.
SellMon Apr 07
Kaufman Jonathan Hdirector, 10 percent owner, officer: See remarks below.
SellMon Mar 17
Kaufman Jonathan Hdirector, 10 percent owner, officer: See remarks below.
SellMon Mar 17
Kaufman Jonathan Hdirector, 10 percent owner, officer: See remarks below.
SellTue Mar 11

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

Beta

0.84

Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. The company was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.

Peers